Treatment of malignant pheochromocytoma

Hormone and Metabolic Research

Volumn 41, Issue 9, 2009, Pages 687-696

  Adjalle R ^a   Plouin, P F ^b   Pacak, K ^c   Lehnert, H ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Adrenal mass; Paraganglioma; Pheochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE(3) OCTREOTIDE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOPEPTIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; CYCLOPHOSPHAMIDE; DACARBAZINE; EVEROLIMUS; INDIUM 111; IODINE 123; LUTETIUM 177; OCTREOTIDE; PASIREOTIDE; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE; YTTRIUM 90;

ANOREXIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CATECHOLAMINE EXCRETION; DRUG ACTIVITY; DRUG MEGADOSE; ENDOCRINE TUMOR; HEAD AND NECK TUMOR; HUMAN; HYPOTHYROIDISM; LONG TERM CARE; METASTASIS; MOLECULAR THERAPY; MONOTHERAPY; NAUSEA; PARAGANGLIOMA; PATHOGENESIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE; REVIEW; THROMBOCYTOPENIA; TUMOR REGRESSION; VOMITING;

ADRENAL GLAND NEOPLASMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG THERAPY; HUMANS; PHEOCHROMOCYTOMA; RADIOTHERAPY;

EID: 70350378805     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0029-1231025     Document Type: Review

References (92)

1. Manger WM. An overview of pheochromocytoma: history, current concepts, vagaries, and diagnostic challenges. Ann N Y Acad Sci 2006 1073 1-20
2. McNeil AR, Blok BH, Koelmeyer TD, Burke MP, Hilton JM. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust N Z J Med 2000 30 648-652
3. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002 346 1459-1466
4. Tischler AS. Pheochromocytoma and extra-adrenal paraganglioma: updates. Arch Pathol Lab Med 2008 132 1272-1284
5. Strong VE, Kennedy T, Al Ahmadie H, Tang L, Coleman J, Fong Y, Brennan M, Ghossein RA. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 2008 143 759-768
6. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 2002 26 551-566
7. Wu LT, Dicpinigaitis P, Bruckner H, Manger W, Averbuch S. Hypertensive crises induced by treatment of malignant pheochromocytoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Med Pediatr Oncol 1994 22 389-392
8. Goldstein RE, ONeill Jr JA, Holcomb GW III, Morgan WM III, Neblett WW III, Oates JA, Brown N, Nadeau J, Smith B, Page DL, Abumrad NN, Scott Jr HW. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999 229 755-764
9. Scholz T, Schulz C, Klose S, Lehnert H. Diagnostic management of benign and malignant pheochromocytoma. Exp Clin Endocrinol Diabetes 2007 115 155-159
10. Favier J, Plouin PF, Corvol P, Gasc JM. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol 2002 161 1235-1246
11. Salmenkivi K, Haglund C, Arola J, Heikkila P. Increased expression of tenascin in pheochromocytomas correlates with malignancy. Am J Surg Pathol 2001 25 1419-1423 (Pubitemid 33022058)
12. Salmenkivi K, Heikkila P, Liu J, Haglund C, Arola J. VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. APMIS 2003 111 458-464
13. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A, Niccoli-Sire P, Richard S, Rohmer V, Sadoul JL, Strompf L, Schlumberger M, Bertagna X, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 2005 23 8812-8818
14. Rao F, Keiser HR, OConner DT. Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. Hypertension 2000 36 1045-1052
15. Capella C, Riva C, Cornaggia M, Chiaravalli AM, Frigerio B, Solcia E. Histopathology, cytology and cytochemistry of pheochromocytomas and paragangliomas including chemodectomas. Pathol Res Pract 1988 183 176-187
16. Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H, Manger WM, Maris JM, Neumann HP, Pacak K, Shulkin BL, Smith DI, Tischler AS, Young WF. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 2004 11 423-436
17. Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, Volk B, Kirste G. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993 329 1531-1538
18. Tanaka S, Ito T, Tomoda J, Higashi T, Yamada G, Tsuji T. Malignant pheochromocytoma with hepatic metastasis diagnosed 20 years after resection of the primary adrenal lesion. Intern Med 1993 32 789-794
19. Pommier RF, Vetto JT, Billingsly K, Woltering EA, Brennan MF. Comparison of adrenal and extraadrenal pheochromocytomas. Surgery 1993 114 1160-1165
20. Sclafani LM, Woodruff JM, Brennan MF. Extraadrenal retroperitoneal paragangliomas: natural history and response to treatment. Surgery 1990 108 1124-1129
21. Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol 1992 147 1-10
22. Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 1997 20 648-658
23. Eisenhofer G, Siegert G, Kotzerke J, Bornstein SR, Pacak K. Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. Horm Metab Res 2008 40 329-337
24. Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC, Kloppenborg PW, Thien T, Eisenhofer G. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med 1995 123 101-109
25. Sjoberg RJ, Simcic KJ, Kidd GS. The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls. Arch Intern Med 1992 152 1193-1197
26. Cleary S, Phillips JK, Huynh TT, Pacak K, Fliedner S, Elkahloun AG, Munson P, Worrell RA, Eisenhofer G. Chromogranin a expression in phaeochromocytomas associated with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Horm Metab Res 2007 39 876-883
27. Grossrubatscher E, Dalino P, Vignati F, Gambacorta M, Pugliese R, Boniardi M, Rossetti O, Marocchi A, Bertuzzi M, Loli P. The role of chromogranin A in the management of patients with phaeochromocytoma. Clin Endocrinol (Oxf) 2006 65 287-293
28. Havekes B, Lai EW, Corssmit EP, Romijn JA, Timmers HJ, Pacak K. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Q J Nucl Med Mol Imaging 2008 52 419-429
29. Takano A, Oriuchi N, Tsushima Y, Taketomi-Takahashi A, Nakajima T, Arisaka Y, Higuchi T, Amanuma M, Endo K. Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy. Ann Nucl Med 2008 22 395-401
30. Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazurova I, Adams KT, Perera S, Pacak K. Comparison of 618F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111In-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med 2008 49 1613-1619
31. Timmers HJ, Eisenhofer G, Carrasquillo JA, Chen CC, Whatley M, Ling A, Adams KT, Pacak K. Use of 6-[18F]-fluorodopamine positron emission tomography as first-line investigation for the diagnosis and localization of non-metastatic and metastatic pheochromocytoma. Clin Endocrinol (Oxf) 2008 Dec 5 Epub ahead of print]
32. Hoegerle S, Nitzsche E, Altehoefer C, Chen CC, Whatley M, Ling A, Adams KT, Pacak K. Pheochromocytomas: detection with 18F DOPA whole body PETinitial results. Radiology 2002 222 507-512
33. Pacak K, Ilias I, Adams KT, Eisenhofer G. Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med 2005 257 60-68
34. Takahashi K, Ashizawa N, Minami T, Suzuki S, Sakamoto I, Hayashi K, Tomiyasu S, Sumikawa K, Kitamura K, Eto T, Yano K. Malignant pheochromocytoma with multiple hepatic metastases treated by chemotherapy and transcatheter arterial embolization. Intern Med 1999 38 349-354
35. Tada K, Okuda Y, Yamashita K. Three cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine, and dacarbazine combination chemotherapy and alpha-methyl-p-tyrosine to control hypercatecholaminemia. Horm Res 1998 49 295-297
36. Nonaka K, Makuuchi H, Naruse Y, Kobayashi T, Goto M. Surgical excision of malignant pheochromocytoma in the left atrium. Jpn J Thorac Cardiovasc Surg 2000 48 126-128
37. Huang KH, Chung SD, Chen SC, Chueh SC, Pu YS, Lai MK, Lin WC. Clinical and pathological data of 10 malignant pheochromocytomas: long-term follow up in a single institute. Int J Urol 2007 14 181-185
38. Ahlman H. Malignant pheochromocytoma: state of the field with future projections. Ann N Y Acad Sci 2006 1073 449-464
39. Mannelli M. Management and treatment of pheochromocytomas and paragangliomas. Ann N Y Acad Sci 2006 1073 405-416
40. Brauckhoff M, Gimm O, Dralle H. Preoperative and surgical therapy in sporadic and familial pheochromocytoma. Front Horm Res 2004 31 121-144
41. Lehnert H, Mundschenk J, Hahn K. Malignant pheochromocytoma. Front Horm Res 2004 31 155-162
42. Jaroszewski DE, Tessier DJ, Schlinkert RT, Grant CS, Thompson GB, van Heerden JA, Farley DR, Smith SL, Hinder RA. Laparoscopic adrenalectomy for pheochromocytoma. Mayo Clin Proc 2003 78 1501-1504
43. Joseph L. Malignant phaochromocytoma of the organ of Zuckerkandl with functioning metastases. Br J Urol 1967 39 221-225
44. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, Britton KE, Jenkins PJ, Chew SL, Monson JP, Besser GM, Grossman AB. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol (Oxf) 2001 55 47-60
45. van der HE, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP, Bosman FT, Kwekkeboom DJ. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001 86 685-693
46. Sisson JC, Shapiro B, Beierwaltes WH, Glowniak JV, Nakajo M, Mangner TJ, Carey JE, Swanson DP, Copp JE, Satterlee WG. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 1984 25 197-206
47. Gedik GK, Hoefnagel CA, Bais E, Olmos RA. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2008 35 725-733
48. Kaltsas GA, Mukherjee JJ, Foley R, Britton KE, Grossman AB. Treatment of Metastatic Pheochromocytoma and Paraganglioma With 131I-Meta-Iodobenzylguanidine (MIBG). Endocrinologist 2001 13 321-333
49. Shapiro B, Sisson JC, Wieland DM, Mangner TJ, Zempel SM, Mudgett E, Gross MD, Carey JE, Zasadny KR, Beierwaltes WH. Radiopharmaceutical therapy of malignant pheochromocytoma with 131I-metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med 1991 35 269-276
50. Troncone L, Rufini V. 131I-MIBG therapy of neural crest tumours (review). Anticancer Res 1997 17 1823-1831
51. Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA, Fitzgerald PA. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 2009 98 239-248
52. Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, Reynolds CP, Seeger RC, Weinberg VK, Price D. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998 16 229-236
53. Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ, Dela Cruz F, Jahan TM, Linker CA, Damon L, Matthay KK. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci 2006 1073 465-490
54. Hartley A, Spooner D, Brunt AM. Management of malignant phaeochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands. Clin Oncol (R Coll Radiol) 2001 361-366
55. Weckbecker G, Raulf F, Stolz B, Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 1993 60 245-264
56. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999 20 157-198
57. Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, Mueller-Brand J, Broelsch CE. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 2006 140 968-976
58. Hubalewska-Dydejczyk A, Trofimiuk M, Sowa-Staszczak A, Gilis-Januszewska A, Wierzchowski W, Pach D, Budzynski A, Karcz D. Somatostatin receptors expression (SSTR1-SSTR5) in pheochromocytomas. Przegl Lek 2008 65 405-407
59. Invitti C, De MI, Bolla GB, Pecori Giraldi F, Maestri E, Leonetti G, Cavagnini F. Effect of octreotide on catecholamine plasma levels in patients with chromaffin cell tumors. Horm Res 1993 40 156-160
60. Mundschenk J, Unger N, Schulz S, Hollt V, Schulz S, Steinke R, Lehnert H. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 2003 88 5150-5157
61. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jurgensen R, Stein K, Schafer H, Bruns C, Dennler HJ. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996 38 430-438
62. Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albers F, Dullaart RP. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med 2008 49 1232-1237
63. Shulkin BL, Ilias I, Sisson JC, Pacak K. Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann N Y Acad Sci 2006 1073 374-382
64. Lamarre-Cliche M, Gimenez-Roqueplo AP, Billaud E, Baudin E, Luton JP, Plouin PF. Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma. Clin Endocrinol (Oxf) 2002 57 629-634
65. Plouin PF, Bertherat J, Chatellier G, Billaud E, Azizi M, Grouzmann E, Epelbaum J. Short-term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with phaeochromocytoma: a placebo-controlled trial. Clin Endocrinol (Oxf) 1995 42 289-294
66. Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging 2008 52 334-340
67. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002 146 707-716
68. Pasquali D, Rossi V, Conzo G, Pannone G, Bufo P, De Bellis A, Renzullo A, Bellastella G, Colao A, Vallone G, Bellastella A, Sinisi AA. Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. J Mol Endocrinol 2008 40 263-271
69. Scharf Y, Ben Arieh Y, Gellei B. Orbital metastases from extra-adrenal pheochromocytoma. Am J Ophthalmol 1970 69 638-640
70. Philipps AF, McMurtry RJ, Taubman J. Malignant pheochromocytoma in childhood. Am J Dis Child 1976 130 1252-1255
71. Hamilton BP, Cheikh IE, Rivera LE. Attempted treatment of inoperable pheochromocytoma with streptozocin. Arch Intern Med 1977 137 762-765
72. Feldman JM. Treatment of metastatic pheochromocytoma with streptozocin. Arch Intern Med 1983 143 1799-1800
73. Herrera LO, Hossain ZM, Rafal HS, Frelick RW, Ashley PF, Lopez GE. Malignant pheochromocytoma (paraganglioma) of the organ of Zuckerkandl: a study of two cases. J Surg Oncol 1980 14 133-145
74. Bukowski RM, Vidt DG. Chemotherapy trials in malignant pheochromocytoma: report of two patients and review of the literature. J Surg Oncol 1984 27 89-92
75. Srimuninnimit V, Wampler GL. Case report of metastatic familial pheochromocytoma treated with cisplatin and 5-fluorouracil. Cancer Chemother Pharmacol 1991 28 217-219
76. Jirari A, Charpentier A, Popescu S, Boidin P, Eisenmann B. A malignant primary cardiac pheochromocytoma. Ann Thorac Surg 1999 68 565-566
77. Keiser HR, Goldstein DS, Wade JL, Douglas FL, Averbuch SD. Treatment of malignant pheochromocytoma with combination chemotherapy. Hypertension 1985 7 I18-I24
78. Edstrom EE, Hjelm Skog AL, Hoog A, Hamberger B. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol 2003 29 278-283
79. Naoi Y, Tamaki Y, Ooka M, Tsukamoto F, Miyoshi Y, Tanji Y, Taguchi T, Noguchi S. A case of metastatic pheochromocytoma with remarkable response to combination of cyclophosphamide, vincristine and dacarbazine. Gan To Kagaku Ryoho 2003 30 145-149
80. Wu D, Tischler AS, Lloyd RV, Delellis RA, de Krijger R, van Nederveen F, Nose V. Observer Variation in the Application of the Pheochromocytoma of the Adrenal Gland Scaled Score. Am J Surg Pathol 2009 33 599-608
81. Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, Pacak K, Fojo T. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 2008 113 2020-2028
82. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006 24 401-406 (Pubitemid 46630459)
83. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997 23 35-61
84. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007 13 2986-2991
85. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007 14 569-585
86. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006 94 614-619
87. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: Targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 2009 94 386-391
88. Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M, Knox JJ. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 2009 94 5-9
89. Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A, Slavin S. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 2006 13 535-540
90. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008 26 4311-4318
91. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003 3 377-383
92. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988 109 267-273